@article {Gladstone6, author = {Jonathan P. Gladstone and David W. Dodick}, title = {Acute Migraine: Which Triptan?}, volume = {4}, number = {1}, pages = {6--19}, year = {2004}, doi = {10.1111/j.1474-7766.2004.03-205.x}, publisher = {BMJ Publishing Group Ltd}, abstract = {INTRODUCTION Primary headache disorders are the most frequent reason for referral to neurologists worldwide, and most of these patients have migraine (Menken 1996; Sempere et al. 2002; Rajput et al. 1988). Migraine is a common and frequently incapacitating headache disorder characterized by episodic attacks of moderate-to-severe headache, along with various combinations of neurological, gastrointestinal and autonomic symptoms (Goadsby et al. 2002). The one-year prevalence of migraine is 11\% in the United States and Western Europe (6\% for males and 15{\textendash}18\% for females) and one quarter of migraine patients experience one or more attacks per week (Goadsby et al. 2002; Hamelsky et al. 2001). A recent report by the World Health Organization ranks migraine as one of the most disabling chronic conditions and equates a day with severe migraine to the disability associated with a day with quadriplegia, psychosis or dementia (Menken et al. 2000).The aggregate impact of migraine}, issn = {1474-7758}, URL = {https://pn.bmj.com/content/4/1/6}, eprint = {https://pn.bmj.com/content/4/1/6.full.pdf}, journal = {Practical Neurology} }